Huntsville, AL – According to filings with the U.S. Securities and Exchange Commission, Serina Therapeutics is raising $76,230,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Randall Moreadith played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Serina Therapeutics

Serina Therapeutics, Inc. is a privately held pharmaceutical company located at the HudsonAlpha Institute of Biotechnology in Huntsville, Alabama. We have developed a proprietary polymer technology called POZ that is designed to optimize drug delivery to maximize compliance, therapeutic outcomes, safety and quality of life for patients. Serina Therapeutics, Inc. was founded in 2006 by Drs. Milton Harris and Michael Bentley who developed and patented much of the polymer technology known as PEG, or PEGylation, during their work at Shearwater Polymers and Nektar Therapeutics. PEG became widely accepted as the polymer standard for drug development. Today, greater than $120 B of cumulative product sales can be attributed to this technology.

To learn more about Serina Therapeutics, visit http://serinatherapeutics.com/

Contact:
Randall Moreadith, President and Chief Executive Officer
256-327-0566
rmoreadith@serinatherapeutics.com
https://www.linkedin.com/in/randall-moreadith-md-phd-143b3313/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved